文献速递淋巴瘤

评估法维泽利单抗联合帕博利珠单抗相对于帕博利珠单抗在抗PD-1难治性霍奇金淋巴瘤中的疗效

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

本研究通过比较MK-4280-003中接受法维泽利单抗联合帕博利珠单抗治疗的患者与KEYNOTE-087中仅接受帕博利珠单抗进展后治疗的患者,评估法维泽利单抗的相对贡献。结果显示联合治疗客观缓解率为37%,而单药为2%;靶病灶缩小≥50%的患者比例分别为48%和5%。

要点

  • 联合治疗客观缓解率37%,单药2%。
  • 靶病灶缩小≥50%者联合组48%,单药组5%。
  • 靶病灶大小平均变化联合组-49%,单药组-0.4%。

核心结论

  • 在抗PD-1难治性经典霍奇金淋巴瘤中,法维泽利单抗联合帕博利珠单抗相比帕博利珠单抗单药具有更高的缓解率和更大的肿瘤负荷降低,提示法维泽利单抗对MK-4280-003的疗效有实质性贡献。

研究设计与样本

  • 研究比较MK-4280-003中接受法维泽利单抗联合帕博利珠单抗治疗的患者与KEYNOTE-087中仅接受帕博利珠单抗进展后治疗的患者。
  • MK-4280-003纳入27例,KEYNOTE-087纳入81例。
  • MK-4280-003患者接受≥2剂抗PD-1治疗且在末次剂量后12周内进展;KEYNOTE-087合格患者接受>2剂帕博利珠单抗进展后治疗且在末次剂量后12周内进展。
  • 治疗方案为帕博利珠单抗200 mg联合法维泽利单抗200 mg或800 mg,或帕博利珠单抗200 mg静脉注射每3周。
  • 采用自举法比较组间靶病灶大小变化。

主要发现

  • 客观缓解率:法维泽利单抗联合帕博利珠单抗组37%(95%CI 15-51),帕博利珠单抗单药组2%(95%CI 0-6)。
  • 靶病灶缩小≥50%:联合组13例(48%),单药组4例(5%)。
  • 靶病灶大小相对基线的平均变化:联合组-49%,单药组-0.4%。
  • 自举分析中,99.4%的样本显示联合治疗肿瘤负荷下降更明显。

关键数值与推荐

  • 疗效评估依据国际工作组2007标准。
  • KEYNOTE-087的基线肿瘤大小在首次进展时重置。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Favezelimab plus pembrolizumab had promising efficacy in anti-programmed cell death protein 1 (PD-1)-refractory classical Hodgkin lymphoma in MK-4280-003; however, the contribution of favezelimab was unclear. Here, we assessed the relative contribution of favezelimab by comparison with data from participants treated with only pembrolizumab beyond progression in KEYNOTE-087. Participants in MK-4280-003 had received ≥2 doses of anti-PD-1 therapy and progressed <12 weeks of last dose. Participants eligible from KEYNOTE-087 had received >2 doses of pembrolizumab beyond progression, and progressed <12 weeks of last dose. Participants received pembrolizumab 200 mg plus favezelimab 200 mg or 800 mg, or pembrolizumab 200 mg IV every 3 weeks. Change in target lesion size and response per International Working Group 2007 criteria were assessed. Baseline tumor size was reset at first progression for KEYNOTE-087. A bootstrapping method compared change in target lesion size between groups. Twenty-seven participants from MK-4280-003 and 81 from KEYNOTE-087 were included. Objective response rates were 37% (95% confidence interval [CI], 15-51) for favezelimab plus pembrolizumab, and 2% (95% CI, 0-6) for pembrolizumab alone. A clinically meaningful reduction (≥50%) in target lesion size was observed in 13 (48%) vs 4 participants (5%), respectively. The mean change from baseline in target lesion size was -49% and -0.4%. In the bootstrapping analysis, 99.4% of samples showed greater decrease in tumor burden with favezelimab plus pembrolizumab. Favezelimab plus pembrolizumab had a higher response rate and greater reduction in tumor burden vs pembrolizumab alone in anti-PD-1-refractory classical Hodgkin lymphoma, suggesting favezelimab contributed substantially to efficacy in MK-4280-003. The trials were registered at www.clinicaltrials.gov as #NCT03598608 and #NCT02453594.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Armand P, Zinzani PL, Timmerman J, et al. Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma. Blood Adv. 2025. PMID: 40668662. doi:10.1182/bloodadvances.2024014654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。